Clinical suppression of precocious puberty with cetrorelix after failed treatment with GnRH agonist in a girl with gonadotrophin-independent precocious puberty.

Abstract

This report presents the case of a 7-year-old girl with gonadotrophin-independent precocious puberty treated with cetrorelix [gonadotrophin-releasing hormone (GnRH) antagonist] after poor response to GnRH agonist therapy was observed in the endocrinology outpatient clinic. Uterine and ovarian morphology returned to within the normal prepubertal range after GnRH antagonist was injected subcutaneously. Vaginal bleeding stopped completely. The effects of GnRH antagonist treatment were comparable to those of GnRH agonist. The potential advantage of GnRH antagonists would be a clinically significant direct effect on the ovary, if it exists, and GnRH antagonists should be available for use in such children.

• Authors: Meng-Hsing Wu, Shio-Jean Lin, Li-Hsiang Wu, Yueh-Chin Cheng, Yen-Yin Chou, Hsien-An Pan
• Journal: Reproductive biomedicine online (Reprod Biomed Online) Vol. 11 Issue 1 Pg. 18-21 (Jul 2005) ISSN: 1472-6483 [Print] Netherlands
• PMID: 16102281 (Publication Type: Case Reports, Journal Article)

Chemical References

• Gonadotropins
• Hormone Antagonists
• Gonadotropin-Releasing Hormone
• cetrorelix

Topics

• Child
• Child, Preschool
• Female
• Gonadotropin-Releasing Hormone (administration & dosage, agonists, analogs & derivatives, therapeutic use)
• Gonadotropins (metabolism)
• Hormone Antagonists (therapeutic use)
• Humans
• Injections
• Ovary (anatomy & histology, drug effects, physiology)
• Ovulation (drug effects)
• Pregnancy
• Puberty, Precocious (drug therapy, etiology)
• Treatment Failure
• Ultrasonography
• Uterus (diagnostic imaging)